Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy

International Journal of Industrial Chemistry

مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 03 مرداد 1401

نوع مقاله: research article

نویسندگان

Lu Shi؛ Zekang Ye؛ Qian Gu؛ Yong Li^*

Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

چکیده

Objective: To investigate the effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes (ACS) after interventional therapy.
Methods: A total of 208 ACS patients treated in our hospital from January 2021 to December 2022 were separated into observation group and control group. Patients in the control group were received oral rosuvastatin 20 mg/ day. Patients in the observation group were received PCSK9 inhibitor elozumab (Repatha) 140 mg, subcutaneously injection twice a week. The levels of inflammatory factors, cardiac function indexes, clinical effective rate, adverse events, and complications were compared before and after treatment.
Results: After 1 week of treatment and 4 weeks of follow-up, the levels of inflammatory indicators in the observation group were declined relative to the control group (P < 0.05 and P < 0.01). After 4 weeks, LVEF in the observation group was elevated in comparison to the control group, while LVEDD in the observation group was declined compared to the control group (P < 0.05). The incidence of adverse events after treatment in the observation group was declined relative to the control group (P < 0.05). The incidence of complications in the observation group was declined in contrast to the control group (P < 0.05).
Conclusion: Statins combined with PCSK9 inhibitors significantly reduce LDL-C levels in ACS patients undergoing PCI without increasing cardiovascular events or major adverse clinical effects.

کلیدواژه‌ها

ACS؛ PCSK9؛ Statins؛ LDL-C